IVVD vs. GLUE, MCRB, KNTE, BLUE, KRON, PRME, SRRK, CRGX, RGNX, and HLVX
Should you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Monte Rosa Therapeutics (GLUE), Seres Therapeutics (MCRB), Kinnate Biopharma (KNTE), bluebird bio (BLUE), Kronos Bio (KRON), Prime Medicine (PRME), Scholar Rock (SRRK), CARGO Therapeutics (CRGX), REGENXBIO (RGNX), and HilleVax (HLVX). These companies are all part of the "medical" sector.
Monte Rosa Therapeutics (NASDAQ:GLUE) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
Monte Rosa Therapeutics received 2 more outperform votes than Invivyd when rated by MarketBeat users. However, 66.67% of users gave Invivyd an outperform vote while only 40.00% of users gave Monte Rosa Therapeutics an outperform vote.
Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 17.9% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Monte Rosa Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
Monte Rosa Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 166.99%. Invivyd has a consensus price target of $11.33, suggesting a potential upside of 515.94%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Monte Rosa Therapeutics.
Invivyd's return on equity of -74.13% beat Monte Rosa Therapeutics' return on equity.
In the previous week, Invivyd had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 7 mentions for Invivyd and 5 mentions for Monte Rosa Therapeutics. Invivyd's average media sentiment score of 0.63 beat Monte Rosa Therapeutics' score of 0.44 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.
Summary
Invivyd beats Monte Rosa Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Invivyd News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
